KONVOMEP (omeprazole and sodium bicarbonate) by R-Pharm US is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the h+/k+ atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for active benign gastric ulcer ( ), risk of upper gastrointestinal (gi) bleeding in critically ill patients ( ). First approved in 2022.
Drug data last refreshed 4h ago · AI intelligence enriched 7h ago
KONVOMEP is an oral suspension combining omeprazole and sodium bicarbonate, a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+ ATPase enzyme system in gastric parietal cells. It is indicated for active benign gastric ulcer and risk reduction of upper GI bleeding in critically ill patients. The sodium bicarbonate component enables rapid acid neutralization, allowing faster omeprazole absorption and onset of action.
Product is in peak commercial phase with modest Part D utilization (4,389 claims in 2023), indicating a niche market opportunity with potential for targeted expansion strategies.
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has…
Worked on KONVOMEP at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moKONVOMEP presents a niche career opportunity within a specialized gastroenterology/critical care segment with zero current job postings, suggesting either a small established team or a newly launched product with limited expansion. Working on this product offers deep therapeutic expertise in acid suppression but limited visibility compared to high-volume franchises; career mobility may require internal transition planning given modest market size.